Side-by-side · Research reference

N-Acetyl Epitalon AmidatevsSemaglutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED12/45 cited

BFDA-ApprovedFlagship15/53 cited

N-Acetyl Epitalon Amidate

Bioregulator Tetrapeptide · Khavinson School

10 passagesExtra divisionsKhavinson 2004

Telomerase+Enzyme inductionKhavinson 2003

4-AATetrapeptide

SQ · Variable protocols

Semaglutide

GLP-1 RA · FDA-Approved

0.25–2.4 mgWeekly doseWEGOVY (semaglutide) injection 2021

14.9%Body-weight ↓Wilding 2021

~7 daysHalf-lifeWEGOVY (semaglutide) injection 2021

SQ · Abdomen / thigh / arm · Once weekly

01Mechanism of Action

Parameter

N-Acetyl Epitalon Amidate

Semaglutide

Primary target

DNA promoter regions (telomerase, RNA polymerase II, retinal genes)

GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021

Pathway

Peptide → DNA complementary binding → Gene transcription initiation → Telomerase catalytic subunit expression

GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021

Downstream effect

Telomerase enzymatic activity induction, telomere elongation to early-passage length, extension of replicative lifespan in human somatic cellsKhavinson 2003 Khavinson 2004

Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021

Feedback intact?

—

Glucose-dependent insulin release preserves physiological feedback

Origin

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from pineal extract bioregulator research; N-acetyl and C-amide modifications enhance plasma stability

Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021

Antibody development

—

02Dosage Protocols

Parameter

N-Acetyl Epitalon Amidate

Semaglutide

Standard dose

No standardized human dosing in indexed literature

In vitro protocols use direct culture addition; human clinical dosing protocols are in Russian-language literature outside PubMed scope.

—

Frequency

Not specified in candidate papers

Once weekly, same day each week

Evidence basis

In vitro human cell cultureKhavinson 2004 Khavinson 2003

FDA-approved · Phase 3 RCTsWilding 2021 WEGOVY (semaglutide) injection 2021

Cell culture protocol

Addition to human fetal fibroblast culture induced telomerase activity and telomere elongation to early-passage lengthKhavinson 2004

Cells made 10 extra divisions (44 passages total vs 34 in control).

—

Duration

Chronic treatment in aging culture

Sustained effect through late passages.

Indefinite for chronic indication

Discontinuation results in weight regain.

Modification stability

N-acetyl + C-amide caps enhance peptidase resistance

Standard strategy for tetrapeptide stabilization; specifics not quantified in candidates.

—

Standard dose (T2D, Ozempic)

—

0.5–1.0 mg / weekWEGOVY (semaglutide) injection 2021

Standard dose (weight, Wegovy)

—

2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021 Wilding 2021

Titration schedule

—

0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks

Mitigates GI side effects.

Reconstitution

—

Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.

Timing

—

Any time of day, with or without food

Half-life

—

~7 days (168 h)WEGOVY (semaglutide) injection 2021

04Side Effects & Safety

Parameter

N-Acetyl Epitalon Amidate

Semaglutide

Human safety data

Not available in indexed literature

Candidate papers describe in vitro and animal models only.

—

Theoretical telomerase risk

Telomerase activation in somatic cells raises theoretical oncogenic transformation concern

—

In vitro observations

No cytotoxicity reported in human fetal fibroblast cultureKhavinson 2004

—

GI symptoms

—

Nausea, vomiting, diarrhea, constipation (very common)Wilding 2021

Injection site reaction

—

Mild erythema, pruritus

Pancreatitis risk

—

Rare; discontinue if suspectedWEGOVY (semaglutide) injection 2021

Thyroid C-cell tumours

—

Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021

Hypoglycemia

—

Low risk as monotherapy; elevated when combined with sulfonylureas / insulin

Gallbladder events

—

Increased cholelithiasis

Pregnancy / OB

—

ContraindicatedWEGOVY (semaglutide) injection 2021

Heart rate

—

Modest ↑ resting HR (~2-4 bpm)

Absolute Contraindications

N-Acetyl Epitalon Amidate

·Active malignancy or history of cancer — telomerase reactivation may promote tumor cell immortalization

Semaglutide

·Personal or family history of medullary thyroid carcinoma
·Multiple endocrine neoplasia syndrome type 2
·Pregnancy / breastfeeding
·Hypersensitivity to semaglutide

Relative Contraindications

N-Acetyl Epitalon Amidate

·Individuals with hereditary cancer syndromes or high genetic cancer risk

Semaglutide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy (may worsen with rapid glycemic improvement)

05Administration Protocol

Parameter

N-Acetyl Epitalon Amidate

Semaglutide

1. Route

Subcutaneous injection assumed based on peptide class; no specific protocol in candidate papers.

Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.

2. Reconstitution

Standard bacteriostatic water for lyophilized peptides. Exact volume not specified in indexed literature.

SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.

3. Storage

Lyophilized: -20 °C, desiccated. Reconstituted: refrigerate 2–8 °C. N-acetyl and C-amide modifications improve stability vs unprotected tetrapeptide.

Once weekly, same day. Day can be changed if ≥2 days separate doses.

4. Clinical protocols

Human dosing schedules published in Russian-language clinical literature; not indexed in PubMed candidate set.

Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.

5. Needle

—

Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.

06Stack Synergy

N-Acetyl Epitalon Amidate

+ Thymalin

Moderate

View Thymalin →

Both are Khavinson-school bioregulators with epigenetic mechanisms. Thymalin targets thymic transcription factors for immune function, while Epitalon targets telomerase and pineal-axis genes. Combined use theoretically addresses dual axes of aging: replicative senescence and immune decline. Multi-target bioregulator strategy per Khavinson gerontology framework.

Epitalon: Protocol not defined in indexed literature
Thymalin: Tissue-specific bioregulator · separate dosing
Rationale: Complementary transcriptional targets
Primary benefit: Dual-axis aging intervention: cellular senescence + immune restoration

Semaglutide

+ Tirzepatide

Weak

View Tirzepatide →

Combining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.

Note: Stack not recommended — choose one GLP-1 RA
Primary benefit: (none — additive toxicity, no synergy)